RAMOT at Tel Aviv University Ltd.

Targeted filamentous bacteriophages as therapeutic agents

Posted by RAMOT at Tel Aviv University Ltd.Responsive · Innovative Products and Technologies · Israel

Summary of the technology

Targeted drug-carrying filamentous bacteriophages have been developed as a novel therapeutic approach for the treatment of infectious disease and cancer. The phages are genetically-modified to display an antibody or a targeting peptide as a targeting moiety on their surface and are used to deliver a cytotoxic drug to the target. The drug is linked to the phages by means of chemical conjugation through a labile linker subject to controlled release. In the conjugated state the cytotoxic drug is devoid of cytotoxic activity and is activated following its dissociation from the targeting phage at the target site in a temporally and spatially controlled manner.
Project ID : 2-2008-23

Description of the technology

The Technology

Targeted drug-carrying filamentous bacteriophages have been developed as a novel therapeutic approach for the treatment of infectious disease and cancer. The phages are genetically-modified to display an antibody or a targeting peptide as a targeting moiety on their surface and are used to deliver a cytotoxic drug to the target. The drug is linked to the phages by means of chemical conjugation through a labile linker subject to controlled release. In the conjugated state the cytotoxic drug is devoid of cytotoxic activity and is activated following its dissociation from the targeting phage at the target site in a temporally and spatially controlled manner. 

Data-to date

Anti-bacterial efficacy studies using chloramphenicol linked (ester-bond or aminoglycosides) to targeted phages have demonstrated bactericidal effect (>30000 drug molecules per phage).

Anti-cancer efficacy studies using hygromycin and doxorubicin linked to anti ErbB2 IgG expressing phages have demonstrated inhibition of growth in ErbB2 and EGFR over-expressing tumor cells

Preliminary in vivo safety studies (toxicity and immunogenicity) have demonstrated  that IV or IP injection of drug-carrying phages are non-toxic and non-immunogenic up to 1011 phages /single dose. 

Patent status

US 7,985,573

EP WO 2006/095345

 

Project manager

Adi Elkeles
BD Manager

Project researchers

Itai Benhar
T.A.U Tel Aviv University, Life Sciences
Molecular Microbiology-Biotechnology

Iftach Yacoby
T.A.U Tel Aviv University, Life Sciences
Molecular Microbiology-Biotechnology

Related keywords

  • Medicine, Human Health
  • Medical Technology / Biomedical Engineering
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Microbiology Technology
  • Bioinformatics Technology
  • Micro- and Nanotechnology related to Biological sciences
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Bioinformatics Market
  • Therapeutic
  • Clinical Medicine
  • oncology
  • Drug delivery
  • Life Sciences and Biotechnology
  • Oncology / Cancer
  • Pharmaceuticals Indications
  • Infection Diseases

About RAMOT at Tel Aviv University Ltd.

Technology Transfer Office from Israel

Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.